Kang, W.*, Shami, J. J. P.*, Yan, V. K. C., Ye, X., Blais, J. E., Li, X., Lee, V. H. F., Chui, C. S. L., Lai, F. T. T., Wan, E. Y. F., Wong, C. K. H., Wong, I. C. K., & Chan, E. W. (2022). Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study. J Hematol Oncol, 15(1), 66. https://doi.org/10.1186/s13045-022-01265-9
点击次数:
上一条:Kang, W., Huang, C., Yan, V. K. C., Wei, Y., Shami, J. J. P., Li, S. T. H., Yang, Y., Ye, X., Tang, J., Lee, S. F., Lee, V. H. F., Chan, S. L., El Helali, A., Lam, K. O., Ngan, R. K. C., Wong, I. C. K., & Chan, E. W. (2024). Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis. Nat Commun, 15(1), 5657. https://doi.org/10.1038/s41467-024-50037-1
下一条:Kang, W., Peng, K., Yan, V. K. C., Al-Badriyeh, D., Lee, S. F., Yiu, H. H. E., Wei, Y., Li, S. T. H., Ye, X., El Helali, A., Lam, K. O., Lee, V. H. F., Wong, I. C. K., & Chan, E. W. (2024). Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis. J Pharm Policy Pract, 17(1), 2375269. https://doi.org/10.1080/20523211.2024.2375269
